Application of modified Charlson comorbidity index for predicting outcomes following adult living donor liver transplantation

Table 1 Comparison of preoperative characteristics between patients with modified Charlson comorbidity index ≤ 3 and those with modified Charlson comorbidity index > 3, n (%)

Variables		mCCI ≤ 3 (n = 301)	mCCI > 3 (n = 196)	P value
Age (years) (IQR)		49 (42, 57)	57 (50, 61)	< 0.001
Sex, male		252 (83.7)	157 (80.1)	0.30
Body mass index (kg/m2) (IQR)		26 (22.8, 29.7)	27 (23.2, 30)	0.46
Model for end-stage liver disease (IQR)		16 (11, 22)	18 (15, 21)	0.01
Geographical distribution	Indian	191 (63.4)	128 (65.3)	0.58
	Middle East and Egypt	57 (18.9)	26 (13.2)
	Asia (other than India)	26 (8.6)	23 (11.7)
	North Africans	10 (3.3)	6 (3.0)
	Others	17 (5.6)	13 (6.6)
Etiology	Metabolic dysfunction-associated steatohepatitis	59 (19.6)	81 (41.3)	< 0.001
	Ethanol related	53 (17.6)	29 (14.8)
	Viral	18 (6)	15 (7.7)
	Cryptogenic	36 (12)	16 (8.2)
	Autoimmune	27 (9)	10 (5.1)
	Hepatocellular carcinoma	60 (19.9)	34 (17.3)
	Others	48 (15.9)	11 (5.6)
Diabetes mellitus		43 (14.2)	174 (88.7)	< 0.001
Hypertension		56 (18.6)	65 (33.1)	< 0.001
Acute kidney injury		100 (33.2)	96 (48.9)	< 0.001
Chronic kidney disease		0 (0)	20 (10.2)	< 0.001
History of preoperative spontaneous bacterial peritonitis		55 (18.2)	33 (16.8)	0.68
History of preoperative intensive care unit stay with 60 days prior to transplant		97 (32.2)	75 (38.2)	0.16

IQR: Interquartile range; mCCI: Modified Charlson comorbidity index.